Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | HTR5A | P47898 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29961206 | 1.00 | SRD5A1 (0.57) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL427457 | 0.89 | MAPT (0.53) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL261277 | 0.82 | AHR (0.48) | SRD5A1HTR5AHTR1AOPRK1AHR | |
| SCHEMBL29622013 | 0.82 | AHR (0.48) | SRD5A1HTR5AHTR1AOPRK1AHR | |
| SCHEMBL3593984 | 0.78 | NPC1 (0.52) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL25432040 | 0.77 | SRD5A1 (0.41) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL30542860 | 0.77 | SRD5A1 (0.41) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL18885726 | 0.77 | NPC1 (0.50) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL2234486 | 0.77 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL837526 | 0.77 | NPC1 (0.50) | SRD5A1NPC1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-12-11 | — | — | US | disclosed |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-03-11 | — | — | US | disclosed |
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-12-19 | — | — | US | disclosed |
| US-20240208953-A1 | \"Cyclopenta[c]pyrrol Negative Allosteric Modulators of NR2B\ | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-06-27 | — | — | US | disclosed |
| EP-4313041-A1 | NOVEL CYCLOPENTAL[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157072-A | Novel cyclopento [ c ] pyrrole NR2B negative allosteric modulators | 诺华股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| WO-2022204336-A1 | NOVEL CYCLOPENTAL[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | NOVARTIS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| EP-3212630-B1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-05-18 | — | — | EP | disclosed |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CINCOR PHARMA, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2010116270-A1 | EP2/4 AGONISTS | PFIZER INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010116270-A1 | EP2/4 AGONISTS | PFIZER INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2009106534-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106534-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| EP-1499606-B8 | 3, 4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1499606-A1 | 3, 4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6713490-B2 | 6-(2-(4-(3-FLUOROPHENYL)-4-HYDROXY-1-PIPERIDINYL)-1-HYDROXY -ETHYL)-3,4-DIHYDRO-2(1H)-QUINOLINONE; REDUCED INHIBITORY ACTIVITY AT HERG (HUMAN ETHER-A-GO-GO RELATED GENE) POTASSIUM CHANNEL | PFIZER, INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030216430-A1 | 3, 4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists | KAWAMURA MITSUHIRO (JP) | 2003-11-20 | — | — | US | disclosed |
| WO-2003091241-A1 | 3, 4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216430-A1 | 3, 4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists | GRIN3B, GRIN1, GRIN2A | SRD5A1 1977/4885NPC1 1352/4885MAPK13 3650/4885 |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | SRD5A1 309/4885NPC1 221/4885MAPK13 4113/4885 |
| US-20240208953-A1 | \"Cyclopenta[c]pyrrol Negative Allosteric Modulators of NR2B\ | GRIN2C, GRIN2B, GRIN2A | SRD5A1 2141/4885NPC1 2885/4885MAPK13 1097/4885 |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | SRD5A1 309/4885NPC1 221/4885MAPK13 4113/4885 |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | SRD5A1 546/4885NPC1 2039/4885MAPK13 390/4885 |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | SRD5A1 309/4885NPC1 221/4885MAPK13 4113/4885 |
| US-20130072679-A1 | DIHYDROQUINOLINE-2-ONE DERIVATIVES | CYP11B1, CYP11B2, HSD11B1 | SRD5A1 60/4885NPC1 462/4885MAPK13 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.